PD-1/PD-L1单抗在靶向耐药和肺癌术前辅助治疗中的疗效分析研究进展  

Research progress on efficacy analysis of PD-1/PD-L1 monoclonal antibody in targeted drug-resistance and pre-operative adjuvant therapy of lung cancer

作　　者：刘洋(综述) 唐东方 陈晓宇 朱训夏 康宁 付文韬 沈晓咏(审校) LIU Yang;TANG Dong-fang;CHEN Xiao-yu;ZHU Xun-xia;KANG Ning;FU Wen-tao;SHEN Xiao-yong(Department of Thoracic Surgery,Huadong Hospital,Fudan University,Shanghai 200040,China)

机构地区：[1]复旦大学附属华东医院胸外科,上海200040

出　　处：《复旦学报（医学版）》2021年第6期841-846,共6页Fudan University Journal of Medical Sciences

基　　金：上海市自然科学基金(18ZR1413000)。

摘　　要：程序性死亡受体-1(programmed death receptor-1,PD-1)和程序性死亡配体-1(programmed death ligand-1,PD-L1)是重要的免疫调节因子。PD-1与PD-L1结合可抑制T细胞的活化与增殖过程,进而介导癌细胞的免疫逃逸。研究发现PD-1/PD-L1单抗用于术前辅助治疗可显著提高肺癌患者的客观及病理缓解率,对于靶向耐药的患者也有良好的疗效。本文对PD-1/PD-L1单抗在靶向耐药和肺癌术前辅助治疗中的最新进展进行综述,详细列出了免疫治疗能够改善肺癌患者靶向治疗耐药后临床预后的证据,表明免疫治疗在肺癌术前辅助治疗方面具有极大潜力。Programmed death receptor-1(PD-1)and programmed death ligand-1(PD-L1)are important immunoregulatory factors.The binding of PD-1 and PD-L1 works in the activation and proliferation of T cells,thereby mediats the immune escape of cancer cells.Studies have found that PD-1/PD-L1 monoclonal antibody applying in pre-operative adjuvant therapy could significantly improve the objective and pathological remission rate of patients with lung cancer,and it also exert positive influence on patients with targeted drug-resistance.In this study,the recent progress of PD-1/PD-L1 monoclonal antibody in targeted drug-resistance and pre-operative adjuvant therapy of lung cancer is reviewed.Some evidence that immunotherapy could improve the clinical prognosis of patients with drug resistance after treated by targeted therapy are listed.Besides,it shows that immunotherapy has great potential in pre-operative adjuvant therapy of lung cancer.

关 键 词：程序性死亡受体-1(PD-1) 程序性死亡配体-1(PD-L1) 靶向耐药 术前辅助治疗 

分 类 号：R749.3[医药卫生—神经病学与精神病学]